43 completed, 7 unknown, 5 terminated, 3 recruiting. 23 Phase 4, 10 Not applicable, 7 Phase 1, 6 Phase 2, 6 Phase 3.
Follow Solifenacin: new trials by email Literature Review of Solifenacin trials Research Report on Solifenacin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Melatonin and Solifenacin for Double-J Ureteral Stent Symptoms Solifenacin, Melatonin - Ureteral Stent-Related Symptoms, Ureteral Calculi | Phase 2 | Recruiting | Beni-Suef University | 189 | 2026-05-07 | 2026-06-02 |
| Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females Solifenacin, Tadalafil - Overactive Bladder | Not applicable | Completed | Ain Shams University | 80 | 2025-05-15 | 2025-12-31 |
| Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker Solifenacin, vitamin D, Standard behavioral therapy - Overactive Bladder, Pediatric Disorder | Not applicable | Completed | Xing Liu | 180 | 2024-12-28 | 2025-11-25 |
| Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry) Solifenacin, Mirabegron - Urinary Incontinence in Children | Phase 3 | Recruiting | University of Aarhus | 236 | 2024-06-27 | 2026-06-08 |
| Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ. Tamsulosin, solifenacin - Ureteral Stent-Related Symptom, Alpha Blocker | Phase 4 | Completed | Liaquat National Hospital & Medical College | 60 | 2024-06-13 | 2025-08-11 |
| Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry) Solifenacin, Mirabegron, Solifenacin + Mirabegron - Urinary Incontinence in Children | Phase 4 | Active not recruiting | University of Aarhus | 216 | 2024-05-27 | 2026-06-08 |
| Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO Li-SWT (suprapubic approach), Li-SWT (perineal approach), Li-SWT (combined approach) - Overactive Bladder, Urinary Incontinence, Urge | Not applicable | Completed | Mansoura University | 132 | 2020-07-04 | 2023-06-15 |
| Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI) - Overactive Bladder, Dementia | Phase 4 | Completed | Baylor Research Institute | 12 | 2019-08-05 | 2024-02-02 |
| Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin Mirabegron, Solifenacin - Overactive Bladder Syndrome | Phase 3 | Unknown | Far Eastern Memorial Hospital | 120 | 2019-08-01 | 2023-09-15 |
| Electroacupuncture and Solifenacin for Urgency-predominant Mixed Urinary Incontinence electroacupuncture, sham electroacupuncture, Solifenacin - Mixed Urinary Incontinence, Urgency-predominant Mixed Urinary Incontinence | Not applicable | Unknown | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 282 | 2019-03-01 | 2022-02-04 |
| Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 5589 | 2018-07-20 | 2024-10-16 | |
| A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 805 | 2018-07-19 | 2020-04-22 | |
| Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease solifenacin, Pelvic floor muscle exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 3 | Completed | VA Office of Research and Development | 77 | 2018-03-01 | 2024-09-24 |
| Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia Tamsulosin, Solifenacin, Solifenacin placebo - Benign Prostate Hyperplasia | Phase 3 | Unknown | IlDong Pharmaceutical Co Ltd | 588 | 2016-01-01 | 2016-07-13 |
| A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type Donepezil, Solifenacin - Dementia of Alzheimer's Type | Phase 2 | Completed | Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | 28 | 2015-10-07 | 2019-03-05 |
| Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes solifenacin, mirabegron - Overactive Bladder Syndrome | Phase 4 | Completed | National Taiwan University Hospital | 113 | 2015-09-08 | 2023-03-28 |
| Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin Tamsulosin, Solifenacin, Tamsulosin and solifenacin - LUTS, Benign Prostatic Hyperplasia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 36 | 2014-07-01 | 2016-06-24 |
| A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics Solifenacin - Urinary Bladder, Overactive | Completed | Astellas Pharma Europe B.V. | 2000 | 2014-06-01 | 2016-09-13 | |
| Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects Mirabegron, Solifenacin succinate, Tamsulosin HCl - Healthy Subjects, Pharmacokinetics | Phase 1 | Completed | Astellas Pharma Europe B.V. | 20 | 2014-05-01 | 2014-08-29 |
| Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence acupuncture, solifenacin, PFMT - Urinary Incontinence | Not applicable | Completed | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 500 | 2014-04-01 | 2019-06-06 |
Showing 20 of 59. Sign in to see all of them.
Urinary Bladder, Overactive (30) · Urinary Incontinence (6) · Urinary Incontinence, Urge (6) · Lower Urinary Tract Symptoms (5) · Prostatic Hyperplasia (3) · Nocturia (2) · Breast Neoplasms (1) · Dementia (1) · Diurnal Enuresis (1) · Hot Flashes (1) · Parkinson Disease (1) · Pelvic Organ Prolapse (1) · Ureteral Calculi (1) · Urinary Bladder, Underactive (1) · Urinary Incontinence, Stress (1)
Astellas Pharma Inc (9) · Astellas Pharma Europe B.V. (6) · Astellas Pharma Singapore Pte. Ltd. (2) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (2) · KYU-SUNG LEE (2) · Klinikum der Universität Köln (2) · Loyola University (2) · Mansoura University (2) · National Taiwan University Hospital (2) · University of Aarhus (2) · Adana Numune Training and Research Hospital (1) · Ain Shams University (1) · Allergan (1) · Asan Medical Center (1) · Astellas Pharma Europe Ltd. (1)
United States (16) · South Korea (12) · Germany (6) · Taiwan (5) · United Kingdom (5) · Belgium (4) · Egypt (4) · Canada (3) · China (3) · Czechia (3) · Poland (3) · Denmark (2) · Italy (2) · Japan (2) · Turkey (Türkiye) (2)
Luise Borch, MD, PhD (2) · Wolfram H Jager, PhD (2) · Ahmed Elshal (1) · Ahmed R EL-Nahas, A. Professor (1) · Alan J Wolffe, PhD (1) · Allen C Sherman, PhD (1) · Elizabeth Camille Vaughan, MD MS (1) · Elizabeth Meuller, MD (1) · G W Davila, MD (1) · Hany F Badawy, MD (1) · Holly E Richter, PhD, MD (1)
PMID 37160401, PMID 20690893, PMID 21175373, PMID 21789068, PMID 23171069, PMID 23332882, PMID 24371246, PMID 25006228, PMID 25128002, PMID 25363606, PMID 25401784, PMID 26423260, PMID 26453222, PMID 30611454, PMID 31919102, PMID 32007426, PMID 32020889, PMID 33231929, PMID 36148895, PMID 37148497, PMID 38430402, PMID 40570329, PMID 40633093, PMID 40658410
2008 (2), 2009 (1)